导师风采
王裕
个人信息
Personal Information
- 性别：男
- 导师类型：硕导
- 职称：主任医师
- 该职称任职时间：20220701
联系方式
Contact Information
- 所属院系：北京协和医院
- 所属专业：外科学
- 邮箱 : ywang@pumch.cn
- 工作电话 : 15311860318
个人简介
Personal Profile
北京协和医院神经外科主任医师，教授，硕士研究生导师。主要致力于脑胶质瘤、脑转移瘤等颅内恶性肿瘤的多模态影像引导的精准神经外科手术切除，以及化疗、靶向、免疫及生物治疗在内的综合治疗。目前担任中国抗癌协会脑胶质瘤专业委员会委员、中国神经科学学会神经肿瘤分会委员、中国胶质瘤协作组委员、北京医学奖励基金会脑转移瘤专家委员会秘书长、世界华人医师协会智慧医疗委员会委员等学术职务。主持及参与医院、院校、省市级课题10项，作为执行研究者参与20项临床试验。已以第一作者或通讯作者发表SCI论文62篇，总IF 330分，其中Q1区11篇，IF＞20分1篇（IF=28.5），IF＞10分5篇，中文核心期刊论文7篇。曾获2022年北京医学科技奖二等奖（第二完成人），北京协和医院2023年科研“先进个人奖（青年领军人才）”和“个人三等功”称号。
团队简介
Team Profile
北京协和医院神经外科脑恶性肿瘤团队由马文斌教授和王裕教授共同领导，成员包括6名博士后（2名出站留院，4名在站）、多名硕博士研究生和协和八年制、4加4试点班学生。团队主要致力于脑胶质瘤、脑转移瘤的临床和基础研究，与清华大学、北京航天航空大学、北京交通大学、协和基础医学研究所等院校及机构合作，开展脑胶质瘤多模态影像组学研究、脑胶质瘤发生与耐药研究、植入式肿瘤治疗电场设备研发等研究。
- 研究方向Research Directions
神经外科-中枢神经系统恶性肿瘤方向
- 在校研究生Current Graduate Students
硕士研究生 3 名，博士研究生 0 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 神经外科本科生教学临床技能培训探索 | 2023-07-31 —— 2025-12-31 | 5万 | 主持的企业/行业委托重大项目 | 主持人 |
| 2 | 载脂蛋白B mRNA编辑酶催化多肽样蛋白3G（APOBEC3G）在胶质母细胞瘤中的作用及分子机制研究 | 2016-11-01 —— 2018-11-30 | 10万 | 主持的企业/行业委托重大项目 | 主持人 |
| 3 | 多模态MRI融合新型PET探针引导下机器人辅助胶质母细胞瘤立体定向多点活检研究 | 2022-07-01 —— 2024-12-01 | 50万 | 主持的企业/行业委托重大项目 | 主持人 |
| 4 | 成纤维细胞激活蛋白在胶质母细胞瘤中的作用和机制研究 | 2020-01-01 —— 2022-12-01 | 20万 | 主持在研的国家或省部级科研项目 | 主持人 |
| 5 | 超声造影与增强MRI在高级别胶质瘤术中应用的一致性研究 | 2024-05 —— 2026-04 | 15万 | 主持的企业/行业委托重大项目 | 主持人 |
| 6 | 多模态影像组学对于脑胶质瘤MGMT启动子甲基化状态预测 | 2018-01 —— 2019-12 | 10万 | 主持的企业/行业委托重大项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas | EUROPEAN JOURNAL OF RADIOLOGY | 2019-12-01 | 通讯作者 |
| 2 | Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses | AGING-US | 2020-07-01 | 通讯作者 |
| 3 | Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures | Cancer Med-US | 2020-12-01 | 通讯作者 |
| 4 | Thin-Slice Magnetic Resonance Imaging-Based Radiomics Signature Predicts Chromosomal 1P/19q Co-deletion Status in Grade II and III Gliomas | Frontiers in Neurology | 2020-10-01 | 通讯作者 |
| 5 | Progress and Prospects of Recurrent Glioma: A Recent Scientometric Analysis of the Web of Science in 2019 | WORLD NEUROSURGERY | 2020-02-01 | 通讯作者 |
| 6 | Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma | CLINICAL RADIOLOGY | 2019-10-01 | 通讯作者 |
| 7 | Prognostic Prediction Model for Glioblastoma: A Metabolic Gene Signature and Independent External Validation | Journal of Cancer | 2021-05-01 | 通讯作者 |
| 8 | Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients | BRIEFINGS IN BIOINFORMATICS | 2021-04-01 | 通讯作者 |
| 9 | Role of Traditional CHO PET Parameters in Distinguishing IDH, TERT and MGMT Alterations in Primary Diffuse Gliomas | ANNALS OF NUCLEAR MEDICINE | 2021-04-01 | 通讯作者 |
| 10 | 18F-Boramino Acid PET/CT in Healthy Volunteers and Glioma Patients. | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021-02-01 | 通讯作者 |
| 11 | investigation of genetic determinants of glioma immune phenotype by integrative immunogenomic scale analysis | Frontiers in Immunology | 2021-06-01 | 通讯作者 |
| 12 | Comprehensive ability evaluation and trend analysis of patients with malignant intracranial tumors in the perisurgery period | Brain and Behavior | 2021-05-31 | 通讯作者 |
| 13 | Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors | NUCLEAR MEDICINE AND BIOLOGY | 2022-01-10 | 通讯作者 |
| 14 | Larger F-18-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors | EJNMMI Research | 2022-04-18 | 通讯作者 |
| 15 | Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. | JOURNAL OF CELLULAR PHYSIOLOGY | 2022-01-01 | 通讯作者 |
| 16 | Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1/NRF2 and CBS-regulated ferroptosis | ACTA PHARMACOLOGICA SINICA | 2022-11-01 | 通讯作者 |
| 17 | Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors | Frontiers in Oncology | 2023-03-14 | 通讯作者 |
| 18 | An online survival predictor in glioma patients using machine learning based on WHO CNS5 data | Frontiers in Neurology | 2023-05-19 | 通讯作者 |
| 19 | Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023-05-29 | 通讯作者 |
| 20 | Spotlights on adult patients with pediatric-type diffuse gliomas in accordance with the 2021 WHO classification of CNS tumors | Frontiers in Neuroscience | 2023-05-05 | 通讯作者 |
| 21 | Prognostic Prediction Model for Glioblastoma: A Ferroptosis-Related Gene Prediction Model and Independent External Validation | Journal of Clinical Medicine | 2023-02-08 | 通讯作者 |
| 22 | Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma | NEURO-ONCOLOGY | 2023-01-19 | 通讯作者 |
| 23 | Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review | Metabolites | 2022-12-05 | 通讯作者 |
| 24 | Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma | Cell Communication and Signaling | 2023-04-12 | 通讯作者 |
| 25 | Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies | Journal of Clinical Medicine | 2022-09-04 | 通讯作者 |
| 26 | Tumor-Treating Fields in Glioblastomas: Past, Present, and Future | Cancers | 2022-07-28 | 通讯作者 |
| 27 | Palliative care for patients with glioma: A recent scientometric analysis of the Web of Science in 2022 | Frontiers in Oncology | 2022-12-13 | 通讯作者 |
| 28 | Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis | PHARMACOLOGICAL RESEARCH | 2022-08-11 | 通讯作者 |
| 29 | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy | Journal of Hematology & Oncology | 2022-10-25 | 通讯作者 |
| 30 | Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation | Journal of Cancer | 2022-01-01 | 通讯作者 |
| 31 | Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress | Frontiers in Oncology | 2021-08-24 | 通讯作者 |
| 32 | Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors. | Cells | 2021-05-01 | 通讯作者 |
| 33 | NTRK fusions and TRK inhibitors: potential targeted therapies for adult glioblastoma. | Frontiers in Oncology | 2020-11-01 | 通讯作者 |
| 34 | Effects of oncolytic viruses and viral vectors on immunity in glioblastoma | GENE THERAPY | 2020-10-01 | 通讯作者 |
| 35 | Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis | Frontiers in Oncology | 2021-03-01 | 通讯作者 |
| 36 | Diffuse leptomeningeal glioneuronal tumour (DLGNT) with hydrocephalus as an initial symptom: a case-based update | CHILDS NERVOUS SYSTEM | 2020-03-01 | 通讯作者 |
| 37 | IFN-γ Triggered IFITM2 Expression to Induce Malignant Phenotype in Elderly GBM | JOURNAL OF MOLECULAR NEUROSCIENCE | 2023-10-27 | 通讯作者 |
| 38 | Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors | Frontiers in Oncology | 2023-07-06 | 通讯作者 |
| 39 | Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors. | Cancer Medicine | 2023-09-01 | 通讯作者 |
| 40 | Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors | Frontiers in Neuroscience | 2024-02-26 | 通讯作者 |
| 41 | Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients | Cancer Medicine | 2024-05-18 | 通讯作者 |
| 42 | A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy | Discover Oncology | 2024-03-22 | 通讯作者 |
| 43 | Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification | JOURNAL OF MOLECULAR NEUROSCIENCE | 2024-02-05 | 通讯作者 |
| 44 | Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data | CNS Neuroscience & Therapeutics | 2024-02-04 | 通讯作者 |
| 45 | A bis-boron boramino acid PET tracer for brain tumor diagnosis | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024-01-09 | 通讯作者 |
| 46 | Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration | METABOLIC BRAIN DISEASE | 2024-04-30 | 通讯作者 |
| 47 | Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors | CANCER LETTERS | 2024-01-28 | 通讯作者 |
| 48 | Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma | NEURO-ONCOLOGY | 2021-02-01 | 通讯作者 |
| 49 | A reply to the letter to the editor by Jaskaran Singh Gosal with regard to the paper "Diffuse leptomeningeal glioneuronal tumour (DLGNT) with hydrocephalus as an initial symptom: a case-based update" | CHILDS NERVOUS SYSTEM | 2020-07-01 | 通讯作者 |
| 50 | B7-H3 in Brain Malignancies: Immunology and Immunotherapy | International Journal of Biological Sciences | 2023-07-24 | 通讯作者 |
| 51 | 老年高级别胶质瘤的临床特点和治疗 | 中华神经外科 | 2020-02 | 通讯作者 |
| 52 | 脑转移瘤患者单纯手术治疗与手术联合术后脑部放疗对比分析 | 中国现代神经疾病杂志 | 2021-02 | 通讯作者 |
| 53 | 基于美国SEER数据库的儿童胶质瘤临床特点和预后分析 | 中国现代神经疾病杂志 | 2021-03 | 通讯作者 |
| 54 | Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study | Cancer medicine | 2024-07 | 通讯作者 |
| 55 | Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution | Cell communication and signaling | 2024-06 | 通讯作者 |
| 56 | The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis | BMC neurology | 2024-06 | 通讯作者 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 202202011P1401 | 脑胶质瘤全病程管理体系的建立及应用推广 | 省部级 | 北京医学科技奖 | 二等奖 | 2023-07-26 | 北京医学会 | 是 | 1 | 2 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 出版高水平专著 | 脑肿瘤免疫治疗及转化研究 |
| 2 | 出版高水平专著 | 中国脑胶质瘤临床管理指南2020 |
| 3 | 出版高水平专著 | 颅脑肿瘤外科学 |
| 4 | 出版高水平专著 | 协和临床外科手册 |
| 5 | 作为主创人员获得授权的发明专利和新品种 | 植入式电极装置及其制备方法 |
| 6 | 获得省部级及以上科研奖励 | 脑胶质瘤全病程管理体系的建立及应用推广 |